2026 Q1 -tulosraportti
Äänite tulossa
1 päivä sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenIf one believes in the project, then just check that the price was significantly higher a few years ago when the development phase was far from where they stand PT. I know it's all about finances. But if one has the product which I believe AlZ is heading towards, then money should not be an issue, as in that case it's about partnership etc. which ALZ is also working on PT. Exciting. time..·1 päivä sittenNo, that is correct, It's probably about visibility, and therefore it's fantastic that ALZ has been invited to make the company's vaccine candidate ALZ-101 visible in the journal Alzheimer's Research & Therapy. A collaboration with a partner, is probably not without the partner investing in the case. We'll see...
·1 päivä sittenThere will probably be a good rise here now after yesterday's news.
·1 päivä sittenHardly! This smells strongly of the release of irrelevant news before a poor financial report tomorrow. Perhaps even yet another wonderful piece of news that the company again needs to raise new capital. I hope for the best but am skeptical.
27.4.27.4.Is there any chance to raise new capital? The warrants are rotten and there are no major shareholders to provide commitments in any future share issue. Controlled shutdown is the the most likely scenario?·27.4.I agree with you. I think the share issue has been a disaster for the existing shareholders, just as is the case with the warrants. The company should be seriously embarrassed. The patient shareholders have been used as a cash cow without the company being able to perform as expected. The clock is ticking for alzinova, and the closer we get to summer, the more shareholders will abandon ship with a big loss. As I have mentioned: it is poor management, poor planning, and poor execution. At least so far
·23.4.What is expected is that they will be able to announce a partner for the start of the Phase 2 study for ALZ-101 during the year. They already have promising results from completed Phase 1 and FDA Fast Track guaranteed. One hopes that one of the interested parties they have recently held talks with will bite, otherwise there is an opportunity at two major Alzheimer's conventions towards summer.·23.4.It's not really the company's info in the annual report that's a problem. It's fairly standard to reserve the right to raise additional capital. It's more that the stock reacts so strongly to it. Volume has been low lately, but it has increased after today's news. And that's because people are losing confidence in the company. And that is, in my opinion, because the company, on the back of an issue that has cost shareholders money, is not delivering on its ambitions. The company should have found a financial partner before the annual report, but they haven't. And that is weak.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Äänite tulossa
1 päivä sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenIf one believes in the project, then just check that the price was significantly higher a few years ago when the development phase was far from where they stand PT. I know it's all about finances. But if one has the product which I believe AlZ is heading towards, then money should not be an issue, as in that case it's about partnership etc. which ALZ is also working on PT. Exciting. time..·1 päivä sittenNo, that is correct, It's probably about visibility, and therefore it's fantastic that ALZ has been invited to make the company's vaccine candidate ALZ-101 visible in the journal Alzheimer's Research & Therapy. A collaboration with a partner, is probably not without the partner investing in the case. We'll see...
- ·1 päivä sittenThere will probably be a good rise here now after yesterday's news.·1 päivä sittenHardly! This smells strongly of the release of irrelevant news before a poor financial report tomorrow. Perhaps even yet another wonderful piece of news that the company again needs to raise new capital. I hope for the best but am skeptical.
- 27.4.27.4.Is there any chance to raise new capital? The warrants are rotten and there are no major shareholders to provide commitments in any future share issue. Controlled shutdown is the the most likely scenario?·27.4.I agree with you. I think the share issue has been a disaster for the existing shareholders, just as is the case with the warrants. The company should be seriously embarrassed. The patient shareholders have been used as a cash cow without the company being able to perform as expected. The clock is ticking for alzinova, and the closer we get to summer, the more shareholders will abandon ship with a big loss. As I have mentioned: it is poor management, poor planning, and poor execution. At least so far
- ·23.4.What is expected is that they will be able to announce a partner for the start of the Phase 2 study for ALZ-101 during the year. They already have promising results from completed Phase 1 and FDA Fast Track guaranteed. One hopes that one of the interested parties they have recently held talks with will bite, otherwise there is an opportunity at two major Alzheimer's conventions towards summer.·23.4.It's not really the company's info in the annual report that's a problem. It's fairly standard to reserve the right to raise additional capital. It's more that the stock reacts so strongly to it. Volume has been low lately, but it has increased after today's news. And that's because people are losing confidence in the company. And that is, in my opinion, because the company, on the back of an issue that has cost shareholders money, is not delivering on its ambitions. The company should have found a financial partner before the annual report, but they haven't. And that is weak.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
2026 Q1 -tulosraportti
Äänite tulossa
1 päivä sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenIf one believes in the project, then just check that the price was significantly higher a few years ago when the development phase was far from where they stand PT. I know it's all about finances. But if one has the product which I believe AlZ is heading towards, then money should not be an issue, as in that case it's about partnership etc. which ALZ is also working on PT. Exciting. time..·1 päivä sittenNo, that is correct, It's probably about visibility, and therefore it's fantastic that ALZ has been invited to make the company's vaccine candidate ALZ-101 visible in the journal Alzheimer's Research & Therapy. A collaboration with a partner, is probably not without the partner investing in the case. We'll see...
- ·1 päivä sittenThere will probably be a good rise here now after yesterday's news.·1 päivä sittenHardly! This smells strongly of the release of irrelevant news before a poor financial report tomorrow. Perhaps even yet another wonderful piece of news that the company again needs to raise new capital. I hope for the best but am skeptical.
- 27.4.27.4.Is there any chance to raise new capital? The warrants are rotten and there are no major shareholders to provide commitments in any future share issue. Controlled shutdown is the the most likely scenario?·27.4.I agree with you. I think the share issue has been a disaster for the existing shareholders, just as is the case with the warrants. The company should be seriously embarrassed. The patient shareholders have been used as a cash cow without the company being able to perform as expected. The clock is ticking for alzinova, and the closer we get to summer, the more shareholders will abandon ship with a big loss. As I have mentioned: it is poor management, poor planning, and poor execution. At least so far
- ·23.4.What is expected is that they will be able to announce a partner for the start of the Phase 2 study for ALZ-101 during the year. They already have promising results from completed Phase 1 and FDA Fast Track guaranteed. One hopes that one of the interested parties they have recently held talks with will bite, otherwise there is an opportunity at two major Alzheimer's conventions towards summer.·23.4.It's not really the company's info in the annual report that's a problem. It's fairly standard to reserve the right to raise additional capital. It's more that the stock reacts so strongly to it. Volume has been low lately, but it has increased after today's news. And that's because people are losing confidence in the company. And that is, in my opinion, because the company, on the back of an issue that has cost shareholders money, is not delivering on its ambitions. The company should have found a financial partner before the annual report, but they haven't. And that is weak.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt